IL209361A0 - Combination therapy with pm00104 and another antitumor agent - Google Patents

Combination therapy with pm00104 and another antitumor agent

Info

Publication number
IL209361A0
IL209361A0 IL209361A IL20936110A IL209361A0 IL 209361 A0 IL209361 A0 IL 209361A0 IL 209361 A IL209361 A IL 209361A IL 20936110 A IL20936110 A IL 20936110A IL 209361 A0 IL209361 A0 IL 209361A0
Authority
IL
Israel
Prior art keywords
combination therapy
antitumor agent
another antitumor
another
agent
Prior art date
Application number
IL209361A
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Doreen Lepage
Pablo Manuel Aviles Marin
Maria Jose Guillen Navarro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa, Doreen Lepage, Pablo Manuel Aviles Marin, Maria Jose Guillen Navarro filed Critical Pharma Mar Sa
Publication of IL209361A0 publication Critical patent/IL209361A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL209361A 2008-05-16 2010-11-16 Combination therapy with pm00104 and another antitumor agent IL209361A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5372608P 2008-05-16 2008-05-16
PCT/US2009/044334 WO2009140675A2 (en) 2008-05-16 2009-05-18 Combination therapy with an antitumor alkaloid

Publications (1)

Publication Number Publication Date
IL209361A0 true IL209361A0 (en) 2011-01-31

Family

ID=41136781

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209361A IL209361A0 (en) 2008-05-16 2010-11-16 Combination therapy with pm00104 and another antitumor agent

Country Status (12)

Country Link
US (1) US20110070232A1 (enExample)
EP (1) EP2307003A2 (enExample)
JP (1) JP2011520921A (enExample)
KR (1) KR20110025178A (enExample)
CN (1) CN102099025A (enExample)
AU (1) AU2009246130A1 (enExample)
CA (1) CA2724325A1 (enExample)
IL (1) IL209361A0 (enExample)
MX (1) MX2010012501A (enExample)
NZ (1) NZ589269A (enExample)
RU (1) RU2010151602A (enExample)
WO (1) WO2009140675A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
HUE042801T2 (hu) 2010-11-12 2019-07-29 Pharma Mar Sa Kombinációs terápia mitózisgátlóval
US9192609B2 (en) * 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN120661674A (zh) * 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
KR102260846B1 (ko) * 2018-07-09 2021-06-07 국립암센터 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1854597A (en) * 1996-01-31 1997-08-22 Board Of Regents, The University Of Texas System Sensitization of HER2/neu over-expressing cancer cells to chemotherapeutic dr ugs
CA2294031E (en) * 1997-07-29 2012-04-03 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
AU770309B2 (en) * 1998-06-05 2004-02-19 Regent Court Technologies Monoamine oxidase (MAO) inhibitors and uses thereof
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
EP1254140A4 (en) * 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0229793D0 (en) * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
EP2301533A1 (en) * 2004-07-09 2011-03-30 University of Pittsburgh Wortmannin Analogs and Method of Using Same
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2006311877A1 (en) * 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
US20070117815A1 (en) * 2005-11-04 2007-05-24 James Pluda Method of treating cancers with SAHA and pemetrexed
EP2043653B1 (en) * 2006-06-21 2013-12-25 Eli Lilly And Company Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
RU2519750C2 (ru) * 2008-05-16 2014-06-20 Фарма Мар, С.А. Способы лечения множественной миеломы

Also Published As

Publication number Publication date
WO2009140675A2 (en) 2009-11-19
CN102099025A (zh) 2011-06-15
KR20110025178A (ko) 2011-03-09
RU2010151602A (ru) 2012-06-27
WO2009140675A3 (en) 2010-04-01
US20110070232A1 (en) 2011-03-24
AU2009246130A1 (en) 2009-11-19
CA2724325A1 (en) 2009-11-19
NZ589269A (en) 2013-03-28
MX2010012501A (es) 2010-12-20
EP2307003A2 (en) 2011-04-13
JP2011520921A (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
IL209361A0 (en) Combination therapy with pm00104 and another antitumor agent
EP2318031A4 (en) IMPROVED METHODS AND DEVICES FOR ANTIVIRAL THERAPY
IL206654A0 (en) Combination therapy
PT3222615T (pt) Agentes de ligação a psma e suas utilizações
IL211742A0 (en) Frizzled-binding agents and uses thereof
GB0803018D0 (en) Therapeutic compounds and their use
GB0804685D0 (en) Therapeutic compounds and their use
IL199992A0 (en) Combination therapy
GB0819280D0 (en) Imgaing and radiotherapy methods
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
EP2268281A4 (en) THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS
IL219768A0 (en) Drug combination with thebromine and its use in therapy
IL219769A0 (en) Drug combination with theromine and its use in therapy
EP2211863A4 (en) COMBINATION THERAPY
GB0812913D0 (en) Therapeutic compounds and their use
PL2313442T3 (pl) Środki dyspergujące i ich zastosowanie
GB0607946D0 (en) Mono and combination therapy
GB0700284D0 (en) Combination therapy
GB0607949D0 (en) Mono and combination therapy
GB0803948D0 (en) Combination therapy
GB0813359D0 (en) Halfin and/or platerfin
EP2252305A4 (en) OMENTUM AND ITS USE
GB0802128D0 (en) Therapeutic compounds and their use
HK1156219A (en) Combination therapy with pm00104 and another antitumor agent